Benzoic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Benzoic acid: antimicrobial and keratolytic agent → bronchitis
One-Sentence Summary
Benzoic acid is a simple aromatic carboxylic acid with weak antimicrobial and keratolytic properties. The TxGNN model predicts it may be effective for bronchitis, but this is a computational prediction only. No clinical trials are registered and none of the retrieved publications studies benzoic acid in this disease, so the evidence level is L5.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | bronchitis |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for benzoic acid in the data compiled for this report. Benzoic acid is known to have weak antimicrobial and keratolytic properties, but nothing in the supplied data connects these properties to airway inflammation or infection.
The high TxGNN score (0.9998) reflects a pattern found by the model and is not evidence of clinical benefit. At present there is no credible mechanistic link between benzoic acid and bronchitis, so the prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22180869 | 2012 | Clinical study | Am J Respir Cell Mol Biol | Soluble epoxide hydrolase inhibitor in smoke-induced COPD (bronchitis is one component of COPD). It does not study benzoic acid. |
| 11577798 | 2001 | Review | Drugs | Review of repaglinide, a benzoic acid derivative, in type 2 diabetes. It is not relevant to bronchitis. |
Neither publication studies benzoic acid in bronchitis.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 105M | Not recorded | Not recorded | Not recorded |
The local data list one valid single-ingredient licence.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. No clinical trial or publication studies benzoic acid in bronchitis, and no mechanistic link is established.
To proceed, the following is needed:
- Mechanism of action data for benzoic acid
- Evidence of a plausible link to airway inflammation or infection, such as preclinical or in vitro studies
- Review of the TGA Product Information for safety warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.